55533A novel multiplex cytokine respiratory panel to change the dynamics of COVID-19 testingClosedFeasibility StudiesInnovate UKThere are a number of markers of inflammation which have been associated with various diseases. One group of such markers is the cytokines which are small proteins released by different cells in the body. These cytokines work as messengers and help co-ordinate the body's fight against infection and inflammation. Cytokines are often measured in the blood of patients with illnesses such as atherosclerosis and cancer. Very recently, a number of cytokines, such as interleukin-6, have been measured in patients infected with the COVID-19 virus and have been found to be significantly increased in those who have suffered worse symptoms and unfortunately, increased death rates. This is due to a 'cytokine storm' when the person's immune system goes into overdrive and becomes out of control. This leads to very high levels of cytokines being released which in turn causes excessive inflammation and even multiple organ damage. Cytokine storms may explain why some people have severe reactions to coronaviruses whilst others end up with only mild symptoms. For lung diseases such as COVID-19, it makes more sense to measure cytokine levels in sputum, as this will be more representative of what is occurring in the lungs themselves. Therefore, the aim of this project is to adapt the existing blood-based tests for three of the key cytokines, including interleukin-6, so that they can be safely and effectively measured in sputum samples. The project will use the extensive expertise of ProAxsis in the development of sputum-based tests to create a new combination test, which enables the level of three key cytokines - Interleukin-6, Interleukin-8 and Tumour Necrosis Factor-alpha - to be measured in a small quantity of sputum. This will help healthcare professionals identify which patients infected with the COVID-19 virus are likely to suffer with the most severe symptoms. In the longer-term, it will also allow them to test the effectiveness of several of the new drugs being developed for the treatment of COVID-19\. ProAxsis will use two of its most experienced scientists to create this new sputum-based combination test within six months, and quickly move to expand its availability to other laboratories throughout the World. The company believes that this will provide a significant new tool for healthcare professionals in the fight against the COVID-19 pandemic. Since the project began, scientists have confirmed how important cytokines such as Interleukin-6 can be as biomarkers for predicting which people who catch the COVID-19 virus will suffer from the worst symptoms. However, they have also very recently shown that measuring the levels of another cytokine, Interleukin-10, in combination with Interleukin-6, provides a better prediction than just considering Interleukin-6 on its own. The Extension for Impact funding will enable the scientists at ProAxsis to use the extra three months to add Interleukin-10 in to the new sputum-based combination test, thereby improving its ability to support healthcare professionals to identify and treat people infected with the COVID-19 virus.